NEULASTIM

This brand name is authorized in Brazil, Ecuador, Hong Kong, Israel, New Zealand, Singapore, Turkey, South Africa

Active ingredients

The drug NEULASTIM contains one active pharmaceutical ingredient (API):

1 Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM

Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Read about Pegfilgrastim

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NEULASTIM Solution for injection	Health Products Regulatory Authority (ZA)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 544117060004007, 544120090005107
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 63-MBE-0716
Country: HK	Department of Health Drug Office	Identifier(s): 54933
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4971
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12080
Country: SG	Health Sciences Authority	Identifier(s): 13200P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699862950145
Country: ZA	Health Products Regulatory Authority	Identifier(s): 42/8.5/0598